These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 10071258)
1. Pharmacologic effects of calcium channel blockers on restenosis. Thaulow E J Cardiovasc Pharmacol; 1999; 33 Suppl 2():S12-6. PubMed ID: 10071258 [TBL] [Abstract][Full Text] [Related]
2. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). Jørgensen B; Simonsen S; Endresen K; Forfang K; Vatne K; Hansen J; Webb J; Buller C; Goulet G; Erikssen J; Thaulow E J Am Coll Cardiol; 2000 Mar; 35(3):592-9. PubMed ID: 10716459 [TBL] [Abstract][Full Text] [Related]
3. Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) Study. Jørgensen B; Thaulow E; Am Heart J; 2003 Jun; 145(6):1030-5. PubMed ID: 12796759 [TBL] [Abstract][Full Text] [Related]
4. Clinical promise of calcium antagonists in the angioplasty patient. Thaulow E; Jörgensen B Eur Heart J; 1997 May; 18 Suppl B():B21-6. PubMed ID: 9152666 [TBL] [Abstract][Full Text] [Related]
5. An updated meta-analysis of calcium-channel blockers in the prevention of restenosis after coronary angioplasty. Dens J; Desmet W; Piessens J Am Heart J; 2003 Mar; 145(3):404-8. PubMed ID: 12660661 [TBL] [Abstract][Full Text] [Related]
6. Results and clinical implications of the CAPARES trial. Thaulow E; Jorgensen B Can J Cardiol; 2000 Jul; 16 Suppl D():8D-11D. PubMed ID: 10932030 [TBL] [Abstract][Full Text] [Related]
7. A pharmacoeconomic evaluation of results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES) in Norway and Canada. Thaulow E; Jorgensen B; Doyle JJ; Casciano R; Casciano J; Kopp Z; Arikian S; Kim R Int J Cardiol; 2002 Jul; 84(1):23-30; discussion 30-2. PubMed ID: 12104059 [TBL] [Abstract][Full Text] [Related]
8. Usefulness of calcium entry blockers during and after percutaneous transluminal coronary artery angioplasty. Schlant RC; King SB Circulation; 1989 Dec; 80(6 Suppl):IV88-92. PubMed ID: 2688988 [TBL] [Abstract][Full Text] [Related]
9. Role of calcium channel blockers in reducing acute ischaemia and preventing restenosis in PTCA. Vahanian A; Lung B Drugs; 1996; 52 Suppl 4():9-15; discussion 15-6. PubMed ID: 8913714 [TBL] [Abstract][Full Text] [Related]
10. A pharmacoeconomic evaluation of amlodipine usage in patients undergoing PTCA in the US using results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES). Thaulow E; Jorgensen B; Doyle JJ; Casciano R; Casciano J; Arikian S; Kim R; Arocho R; Kopp Z J Cardiovasc Manag; 2001; 12(2):31-5. PubMed ID: 11299932 [No Abstract] [Full Text] [Related]
11. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Mason RP Atherosclerosis; 2002 Dec; 165(2):191-9. PubMed ID: 12417269 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty (VESPA) Trial. Bestehorn HP; Neumann FJ; Büttner HJ; Betz P; Stürzenhofecker P; von Hodenberg E; Verdun A; Levai L; Monassier JP; Roskamm H J Am Coll Cardiol; 2004 Jun; 43(12):2160-5. PubMed ID: 15193674 [TBL] [Abstract][Full Text] [Related]
13. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial. Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699 [TBL] [Abstract][Full Text] [Related]
14. Effect of high dose verapamil on restenosis after peripheral angioplasty. Schweizer J; Kirch W; Koch R; Hellner G; Uhlmann K J Am Coll Cardiol; 1998 May; 31(6):1299-305. PubMed ID: 9581724 [TBL] [Abstract][Full Text] [Related]
15. Usefulness of Nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). NIsoldipine in COronary artery disease in LEuven. Dens JA; Desmet WJ; Coussement P; De Scheerder IK; Kostopoulos K; Kerdsinchai P; Supanantaroek C; Piessens JH Am J Cardiol; 2001 Jan; 87(1):28-33. PubMed ID: 11137829 [TBL] [Abstract][Full Text] [Related]
16. Influence of the methodology of percutaneous transluminal coronary angioplasty on restenosis. Douglas JS; King SB; Roubin GS Am J Cardiol; 1987 Jul; 60(3):29B-33B. PubMed ID: 2956837 [TBL] [Abstract][Full Text] [Related]
17. [Calcium antagonists and prevention of post-angioplasty restenosis]. Hoberg E Arch Mal Coeur Vaiss; 1995 Sep; 88 Spec No 4():29-34. PubMed ID: 7503622 [TBL] [Abstract][Full Text] [Related]
18. The Frankfurt experience in restenosis after coronary angioplasty. Bussmann WD; Kaltenbach M; Kober G; Vallbracht C Am J Cardiol; 1987 Jul; 60(3):48B-49B. PubMed ID: 2956842 [TBL] [Abstract][Full Text] [Related]
19. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Serruys PW; Foley DP; Jackson G; Bonnier H; Macaya C; Vrolix M; Branzi A; Shepherd J; Suryapranata H; de Feyter PJ; Melkert R; van Es GA; Pfister PJ Eur Heart J; 1999 Jan; 20(1):58-69. PubMed ID: 10075142 [TBL] [Abstract][Full Text] [Related]
20. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group. Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]